IGC Pharma Statistics
Total Valuation
IGC Pharma has a market cap or net worth of $28.64 million. The enterprise value is $28.47 million.
Important Dates
The next estimated earnings date is Friday, August 15, 2025, after market close.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGC Pharma has 83.89 million shares outstanding. The number of shares has increased by 30.04% in one year.
| Current Share Class | 83.89M |
| Shares Outstanding | 83.89M |
| Shares Change (YoY) | +30.04% |
| Shares Change (QoQ) | +2.52% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 24.42% |
| Float | 76.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.55 |
| Forward PS | 20.71 |
| PB Ratio | 4.36 |
| P/TBV Ratio | 6.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.28 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -104.33% and return on invested capital (ROIC) is -65.39%.
| Return on Equity (ROE) | -104.33% |
| Return on Assets (ROA) | -49.91% |
| Return on Invested Capital (ROIC) | -65.39% |
| Return on Capital Employed (ROCE) | -114.73% |
| Revenue Per Employee | $18,157 |
| Profits Per Employee | -$101,729 |
| Employee Count | 70 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.16% in the last 52 weeks. The beta is 1.48, so IGC Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -25.16% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.33 |
| Relative Strength Index (RSI) | 47.06 |
| Average Volume (20 Days) | 7,604,597 |
Short Selling Information
The latest short interest is 3.46 million, so 4.13% of the outstanding shares have been sold short.
| Short Interest | 3.46M |
| Short Previous Month | 525,944 |
| Short % of Shares Out | 4.13% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 0.50 |
Income Statement
In the last 12 months, IGC Pharma had revenue of $1.27 million and -$7.12 million in losses. Loss per share was -$0.09.
| Revenue | 1.27M |
| Gross Profit | 619,000 |
| Operating Income | -7.45M |
| Pretax Income | -13.30M |
| Net Income | -7.12M |
| EBITDA | -6.83M |
| EBIT | -7.45M |
| Loss Per Share | -$0.09 |
Full Income StatementBalance Sheet
The company has $405,000 in cash and $238,000 in debt, giving a net cash position of $167,000 or $0.00 per share.
| Cash & Cash Equivalents | 405,000 |
| Total Debt | 238,000 |
| Net Cash | 167,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 6.33M |
| Book Value Per Share | 0.08 |
| Working Capital | 639,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.80 million and capital expenditures -$112,000, giving a free cash flow of -$4.91 million.
| Operating Cash Flow | -4.80M |
| Capital Expenditures | -112,000 |
| Free Cash Flow | -4.91M |
| FCF Per Share | -$0.06 |
Full Cash Flow StatementMargins
| Gross Margin | 48.70% |
| Operating Margin | -585.84% |
| Pretax Margin | -560.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGC Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.04% |
| Shareholder Yield | n/a |
| Earnings Yield | -24.86% |
| FCF Yield | -17.13% |
Analyst Forecast
The average price target for IGC Pharma is $3.88, which is 1,036.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.88 |
| Price Target Difference | 1,036.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
IGC Pharma has an Altman Z-Score of -14.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.54 |
| Piotroski F-Score | 3 |
